Sandu Pharmaceuticals launches Sandu Kumarvin
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Strides is the first Indian company to get approval for the product.
Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
The tenure of contract will be upto 10 years from date of signing the contract/installation.
Subscribe To Our Newsletter & Stay Updated